Syra Health earnings release, May 7, 2026

Syra Health Corp (SYRA) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Syra

Health Delivers its First Profitable Quarter in Q1 2026, Expands Margins and Strengthens Financial Position

Carmel,

Ind., May 7, 2026 /

PRNewswire – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the first quarter ended March 31, 2026.

Q1

2026 Financial Highlights

Syra

Health achieved profitability in Q1 2026, with net income of $240,979, compared to a net loss of $(472,265) in the prior year period, an improvement of approximately $713,000.

2026

Financial Outlook

Recent

Operational Highlights

Management

Commentary

Greg

Alexander, CEO of Syra Health, said, “Q1 2026 represents a major milestone for Syra Health as we achieved our first profitable quarter, reflecting the growing strength of our business. This performance was driven by year-over-year revenue growth, significant gross margin expansion, and positive net income and earnings per share. Our population health solutions continue to be a powerful growth engine for us, validating our prevention-focused mission. Ongoing contract renewals and expansions with existing customers further reinforce the value of our offerings, providing strong revenue visibility and signaling long-term customer confidence, an important indicator of stability and sustainable growth for investors. While quarterly results may vary due to contract timing and milestone recognition, we remain confident in our profitability trajectory by year-end, as the fundamentals driving our business— expanding partnerships, growing demand for accessible, affordable, and prevention-focused healthcare solutions, and disciplined execution— remain firmly intact.”

Q1

2026 Financial Results

Revenue for the first quarter of 2026 was $2.3 million, an increase of 22% compared to $1.9 million in the first quarter of 2025. Strong growth was driven by the Company’s high-margin population health solutions, which grew 46% year-over-year to $1.8 million from $1.2 million.

Healthcare workforce solutions decreased, as expected, to approximately $513,000 from $655,000 in the prior period, as the Company strategically prioritizes higher-margin solutions. We expanded our gross profit margin by 11 percentage points to 42.7% compared with 31.7% in the prior year period, due to a revenue mix shift toward higher-margin solutions and improved operating leverage in Population Health.

Operating expenses declined across all major categories, reflecting disciplined cost management and improved operational efficiency. Salaries and benefits decreased 27% from $507,207 in Q1 2025 to $372,109 in Q1 2026. Professional services fell 16% to $187,141 in Q1 2026 from $224,026 in the prior year period. SG&A was reduced by 26% to $213,047 in Q1 2026 when compared to $287,287 in Q1 2025. Research and development expenses declined significantly by 81% to $6,921 for the first quarter of 2026 from $37,173 in the first quarter of 2025. Depreciation declined 85% to $1,054 from $6,797 in the year-ago period.

Adjusted

EBITDA for the first quarter of 2026 was $244,495, a material improvement when compared to ($462,239) in the prior year.

SYRA

HEALTH CORP.

BALANCE

SHEETS

SYRA

HEALTH CORP.

STATEMENTS

OF OPERATIONS

(Unaudited)

SYRA

HEALTH CORP.

STATEMENTS

OF CASH FLOWS

(Unaudited)

Non-GAAP

Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America (“GAAP”), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

Syra

Health Corp EBITDA

About

Syra Health

Syra

Health is an integrated healthcare solutions company serving government and commercial healthcare organizations with innovative solutions designed to improve health outcomes. We specialize in healthcare prevention, expanding access, and delivering affordable solutions. Our healthcare analytics capabilities provide proactive, actionable insights and data-driven intelligence, and our HIPAA-compliant and fully accessible digital health solutions enable measurable health outcomes in highly regulated healthcare environments. Through training and education, we help healthcare organizations reduce costs and deliver consistent, high-quality care.

Discover our healthcare solutions at www.syrahealth.com and follow the Company on

LinkedIn.

Forward-Looking

Statements

Financial statements

Income Statement

For the Three Months Ended — (Unaudited)

For the Three Months Ended – March 31, 2026For the Three Months Ended – March 31, 2025
Net revenues2,273,5201,857,774
Cost of services1,302,2651,268,618
Gross profit971,255589,156
Operating expenses:Salaries and benefits372,109507,207
Operating expenses:Professional services187,141224,026
Operating expenses:Research and development expenses6,92137,173
Operating expenses:Selling, general and administrative expenses213,047287,287
Operating expenses:Depreciation1,0546,797
Operating expenses:Total operating expenses780,2721,062,490
Operating expenses:Operating income (loss)190,983-473,334
Other income (expense):Interest income52,4584,298
Other income (expense):Interest expense-2,462-3,229
Other income (expense):Total other income (expense)49,9961,069
Other income (expense):Net income (loss)240,979-472,265
Other income (expense):Weighted average common shares outstanding - basic11,939,16911,587,058
Other income (expense):Net income (loss) per common share - basic0.02-0.04
Other income (expense):Weighted average common shares outstanding - diluted12,781,48711,587,058
Other income (expense):Net income (loss) per common share - diluted0.02-0.04

Income Statement

Quarter ended — Syra Health Corp EBITDA

Quarter ended – March 31, 2026Quarter ended – March 31, 2025
Net Income (Loss)240,979-472,265
Interest expense2,4623,229
Depreciation expense1,0546,797
Earnings before Interest, Taxes, Depreciation and Amortization244,495-462,239

Balance Sheet

March 31, 2026 — BALANCE SHEETS

March 31, 2026 – (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents2,922,3181,614,733
Current assets:Accounts receivable, net869,132918,374
Current assets:Other current assets136,077205,423
Current assets:Total current assets3,927,5272,738,530
Current assets:Property and equipment, net5,9326,986
Current assets:Right-of-use asset11,06027,401
Current assets:Total assets3,944,5192,772,917
Current liabilities:Accounts payable366,422247,520
Current liabilities:Accounts payable, related party98,50072,000
Current liabilities:Accrued expenses293,486194,821
Current liabilities:Deferred revenue750,52416,611
Current liabilities:Current portion of operating lease liability, related party11,06027,401
Current liabilities:Notes payable62,026116,386
Current liabilities:Total current liabilities1,582,018674,739
Current liabilities:Total liabilities1,582,018674,739
Stockholders’ equity:Class A common stock, $0.001 par value, 100,000,000 shares authorized, 11,339,169 shares issued and outstanding11,33911,339
Stockholders’ equity:Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 600,000 shares issued and outstanding600600
Stockholders’ equity:Additional paid-in capital11,830,10911,806,765
Stockholders’ equity:Accumulated deficit-9,479,547-9,720,526
Stockholders’ equity:Total stockholders’ equity2,362,5012,098,178
Stockholders’ equity:Total liabilities and stockholders’ equity3,944,5192,772,917

Cash Flow

For the Three Months Ended March 31, — (Unaudited)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet income (loss)240,979-472,265
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Depreciation1,0546,797
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Common stock issued for services2,586
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Stock-based compensation23,34432,944
Changes in operating assets and liabilities:Accounts receivable49,242-265,029
Changes in operating assets and liabilities:Other current assets69,34665,775
Changes in operating assets and liabilities:Right-of-use asset16,341244,419
Changes in operating assets and liabilities:Accounts payable118,902223,337
Changes in operating assets and liabilities:Accounts payable, related party26,500
Changes in operating assets and liabilities:Deferred revenue733,913582,602
Changes in operating assets and liabilities:Accrued expenses98,665-18,516
Changes in operating assets and liabilities:Operating lease liability-16,341-244,419
Changes in operating assets and liabilities:Net cash provided by operating activities1,361,945158,231
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from sale of common stock and exercise of warrants14,800
CASH FLOWS FROM FINANCING ACTIVITIESRepayments on notes payable-54,360-77,851
CASH FLOWS FROM FINANCING ACTIVITIESNet cash used in financing activities-54,360-63,051
CASH FLOWS FROM FINANCING ACTIVITIESNET CHANGE IN CASH AND CASH EQUIVALENTS1,307,58595,180
CASH FLOWS FROM FINANCING ACTIVITIESCASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD1,614,7332,395,405
CASH FLOWS FROM FINANCING ACTIVITIESCASH AND CASH EQUIVALENTS AT END OF PERIOD2,922,3182,490,585
SUPPLEMENTAL INFORMATION:Interest paid2,4623,229
SUPPLEMENTAL INFORMATION:Income taxes paid$-$-
NON-CASH INVESTING AND FINANCING ACTIVITIES:Conversion of Class B common stock to Class A common stock$-2,333
Full release

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”... (truncated)” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact

Christine

Drury

IR/PR

Director

Syra

Health

463-345-5180

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Syra Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.